Lame-duck, new Congress face pharma reforms
Today’s ballot box results will determine to a great extent how Washington approaches health care and pharma policy.
Stay updated with breaking news from Research Corner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Today’s ballot box results will determine to a great extent how Washington approaches health care and pharma policy.
The FDA is eyeing a media-savvy public health expert to guide its public relations strategy after a series of flubs on abortion access post-<i>Roe,</i> the infant formula shortage and the pandemic, POLITICO’s Adam Cancryn scoops.
The FDA released briefing documents over the weekend that appeared largely favorable to Pfizer-BioNTech’s and Moderna’s efforts to offer vaccines to babies and toddlers.
Top Republicans on the committee signal the infant formula crisis could hamper efforts to quickly reauthorize FDA user fees.
The pairing of Moderna’s and Pfizer’s youngest-kids requests into one meeting prompted outcries from parent advocates.